Morphine (Chlorhydrate) Lavoisier (Morphine Hydrochloride)

Morphine binds to mu‑opioid receptors in the brain and spinal cord, activating inhibitory pathways that reduce neuronal excitability. This action decreases the release of neurotransmitters involved in pain transmission, resulting in analgesia and sedation. The same mechanism can also depress respiratory centers at high concentrations.

The appropriate dose of morphine is determined by the prescribing clinician based on the patient’s pain severity, prior opioid exposure, route of administration, and individual health status. Dosing regimens vary widely, and adjustments are made to achieve effective analgesia while minimizing adverse effects.

Safety data for morphine in pregnancy and lactation are limited, and the drug is generally classified as contraindicated or used only when the benefit outweighs the risk. Morphine can cross the placenta and be excreted in breast milk, potentially causing respiratory depression in the newborn. Consultation with a specialist is essential.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any temperature‑controlled requirements) and necessary import documentation.

Morphine is considered the gold‑standard opioid for severe pain due to its well‑characterized efficacy and pharmacokinetics. Compared with newer agents such as fentanyl or hydromorphone, morphine has a longer duration of action but may produce more pronounced constipation and histamine release. Choice of agent depends on clinical context, route, and patient tolerance.

Morphine (Chlorhydrate) Lavoisier should be stored at room temperature, below 25 °C, in its original sealed container. Protect the solution from direct light, moisture and extreme temperatures. Follow standard aseptic handling procedures and ensure that any unused portion is disposed of according to local regulations for controlled substances.

The product is supplied as a sterile injectable solution and is administered by trained healthcare professionals via epidural, intracerebroventricular or intrathecal injection. The specific route, volume and infusion rate are determined by the prescriber based on the clinical situation and patient response.

The most critical risks include respiratory depression, severe hypotension, profound sedation leading to coma, and the potential for dependence or addiction. Rare but life‑threatening reactions such as anaphylaxis or adrenal insufficiency may also occur. Continuous monitoring, especially after dose initiation or escalation, is essential.

Morphine is contraindicated in patients with known hypersensitivity to morphine or other opioids, those with severe respiratory insufficiency, uncontrolled asthma, or paralytic ileus. Caution is advised in individuals with significant renal or hepatic impairment, head injury, or a history of substance use disorder. The prescriber must evaluate each case individually.